Centaur Pharmaceuticals Private Limited — Gliclazide Exporter Profile
Indian Pharmaceutical Exporter · #12 for Gliclazide · $1.8M export value · DGFT Verified
Centaur Pharmaceuticals Private Limited is the #12 Indian exporter of Gliclazide with $1.8M in export value and 36 verified shipments. Centaur Pharmaceuticals Private Limited holds a 0.6% market share in Gliclazide exports across 9 countries. The company exports 6 pharmaceutical products worth $11.1M across 4 therapeutic categories.
Centaur Pharmaceuticals Private Limited — Gliclazide Export Profile: Buyers & Destinations
Where Does Centaur Pharmaceuticals Private Limited Export Gliclazide?
| Country | Value | Shipments | Share |
|---|---|---|---|
| CANADA | $250.0K | 7 | 24.0% |
| SLOVAK REPUBLIC | $170.8K | 4 | 16.4% |
| CROATIA | $136.6K | 4 | 13.1% |
| GERMANY | $130.3K | 15 | 12.5% |
| FRANCE | $107.7K | 3 | 10.3% |
| KUWAIT | $100.0K | 4 | 9.6% |
| SLOVAKIA | $80.3K | 2 | 7.7% |
| SPAIN | $67.2K | 2 | 6.4% |
| BULGARIA | $0 | 1 | 0.0% |
| AUSTRALIA | $0 | 2 | 0.0% |
Centaur Pharmaceuticals Private Limited exports Gliclazide to 10 countries. The largest destination is CANADA accounting for 24.0% of Centaur Pharmaceuticals Private Limited's Gliclazide shipments, followed by SLOVAK REPUBLIC (16.4%) and CROATIA (13.1%). These destinations reflect Centaur Pharmaceuticals Private Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Gliclazide from Centaur Pharmaceuticals Private Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| MINT PHARMACEUTICALS INC | CANADA | $200.0K | 4 |
| STADA PHARMA SLOVAKIA, S.R.O. | SLOVAK REPUBLIC | $170.8K | 4 |
| BELUPO LIJEKOVI KOZMETIKA D D ULICA DANICA | CROATIA | $136.6K | 4 |
| MERCKLE GMBH | GERMANY | $130.2K | 4 |
| MAP UNITED PHARMACEUTICAL COMPANY | KUWAIT | $100.0K | 3 |
| PHOENIX ZDRAVONTNICKE ZASOBOVANIE A S DIALNICNA CESTA | SLOVAKIA | $80.3K | 2 |
| LABORATORIO STADA, S.L.U. | SPAIN | $67.2K | 2 |
| EG LABO LABORATOIRES EUROGENERIC | FRANCE | $57.7K | 2 |
| CENTRE SPECIALITES PHARMACEUTIQUES | FRANCE | $50.0K | 1 |
| MINT PHARMACEUTICALS INC. | CANADA | $50.0K | 1 |
Centaur Pharmaceuticals Private Limited supplies Gliclazide to 15 buyers globally. The largest buyer is MINT PHARMACEUTICALS INC (CANADA), followed by STADA PHARMA SLOVAKIA, S.R.O. (SLOVAK REPUBLIC) and BELUPO LIJEKOVI KOZMETIKA D D ULICA DANICA (CROATIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Gliclazide Export Value and How Much Does Centaur Pharmaceuticals Private Limited Contribute?
India exported $68.5M worth of Gliclazide through 3,830 shipments from 238 suppliers to 109 countries, serving 643 buyers globally. Centaur Pharmaceuticals Private Limited contributes $1.8M to this total, accounting for 0.6% of India's Gliclazide exports. Centaur Pharmaceuticals Private Limited ships Gliclazide to 10 countries through 15 buyers.
What Is the Average Shipment Value for Centaur Pharmaceuticals Private Limited's Gliclazide Exports?
Centaur Pharmaceuticals Private Limited's average Gliclazide shipment value is $50.0K per consignment, based on 36 shipments totaling $1.8M. The largest destination is CANADA (24.0% of Centaur Pharmaceuticals Private Limited's Gliclazide exports).
How Does Centaur Pharmaceuticals Private Limited Compare to Other Indian Gliclazide Exporters?
Centaur Pharmaceuticals Private Limited ranks #12 among 238 Indian Gliclazide exporters with a 0.6% market share. The top 3 exporters are SUN PHARMACEUTICAL INDUSTRIES LIMITED ($15.1M), MICRO LABS LIMITED ($7.6M), IPCA LABORATORIES LIMITED ($7.3M). Centaur Pharmaceuticals Private Limited processed 36 shipments to 9 destination countries.
What Gliclazide Formulations Does Centaur Pharmaceuticals Private Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| INDIAN HARMLESS MEDICINES-GLICLAZIDE MOD | $237.9K | 6 |
| INDIAN HARMLESS MEDICINES ASOKA MR 60MG/ GLICLAZIDE MODIFIED RELEASE TABLETS 60 MG - 6X10'S - KW EACH MODIFIED RELEAS | $100.0K | 2 |
| GLICLAZIDE RETARD TEVA 60 MG /GLICLAZIDEMODIFIED RELEASE TABLETS 60 MG - 3X10`S -NL EACH MODIFIED RELEASE TABLET CONTA | $87.2K | 2 |
| INDIAN HARMLESS MEDICINES- GLICLAZIDE EG | $50.0K | 1 |
| MINT GLICLAZIDE MR 30MG TABLETS- PACK SI | $50.0K | 1 |
| INDIAN HARMLESS MEDICINES: GLIKA 60 MG TABLETS / GLICLAZIDE 60 MG MODIFIED RELEASE TABLETS - 3X10`S - HR EACH MODIFIED R | $50.0K | 1 |
| INDIAN HARMLESS MEDICINES: GLIKA 60 MG TABLETS / GLICLAZIDE 60 MG MODIFIED RELEASE TABLETS - 3X10`S - MK EACH MODIFIED R | $50.0K | 1 |
| INDIAN HARMLESS MEDICINES - GLICLAZIDE MODIFIED RELEASE TABLETS 60 MG - 12 X 10'S-SK GLICLAZIDE MR STADA 60 MG EACH MO | $50.0K | 1 |
| INDIAN HARMLESS MEDICINES MINT GLICLAZIDE MR 30MG-100S GLICLAZIDE MODIFIED RELEASE TABLETS 30MG EACH | $50.0K | 1 |
| MINT-GLICLAZIDE MR 60 MG/GLICLAZIDE MODIFIED RELEASE TABLETS 60 MG EACH MODIFIEDRELEASE TABLET CONTAINS:GLICLAZIDE | $50.0K | 1 |
Centaur Pharmaceuticals Private Limited exports 32 distinct Gliclazide formulations including tablets, capsules, syrups, and combination drugs. The top formulation is INDIAN HARMLESS MEDICINES-GLICLAZIDE MOD with 6 shipments worth $237.9K.
Regulatory Requirements: Exporting Gliclazide to Key Markets
What Centaur Pharmaceuticals Private Limited must comply with to export Gliclazide to its top destination countries
Canada — HC
Approval Process
ANDS (Abbreviated New Drug Submission) referencing Canadian Reference Product. Comparative bioavailability study required.
Timeline: 12–18 months
GMP & Export Requirements
Health Canada GMP (GUI-0001); Drug Establishment Licence (DEL) inspection
Drug Identification Number (DIN) for each product; Certificate of Pharmaceutical Product from CDSCO
Note: Subject to Good Import Practices and annual C.01.014.6 review.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Centaur Pharmaceuticals Private Limited Compare to Nearest Gliclazide Exporters?
Exporters ranked immediately above and below #12 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 13 | INVENTIA HEALTHCARE LIMITED | $2.0M | 134 | 6 | $14.8K |
| 14 | ALKEM LABORATORIES LIMITED | $2.0M | 68 | 2 | $29.2K |
| 12 | CENTAUR PHARMACEUTICALS PRIVATE LIMITED ★ | $1.8M | 36 | 9 | $50.0K |
| 15 | WALLACE PHARMACEUTICALS PRIVATE LIMITED | $1.1M | 22 | 1 | $50.0K |
Centaur Pharmaceuticals Private Limited ranks #12 among 238 Indian Gliclazide exporters. Average shipment value of $50.0K compared to the market average of $287.6K. The closest competitors by value are INVENTIA HEALTHCARE LIMITED and ALKEM LABORATORIES LIMITED.
Which Indian Ports Ship Gliclazide Exports?
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 439 | 11.5% |
| SAHAR AIR | 375 | 9.8% |
| JNPT/ NHAVA SHEVA SEA | 323 | 8.4% |
| SAHAR AIR CARGO ACC (INBOM4) | 247 | 6.4% |
| DELHI AIR | 229 | 6.0% |
| JNPT | 203 | 5.3% |
| DELHI AIR CARGO ACC (INDEL4) | 165 | 4.3% |
| CMA CGM LOGISTICS PARK ICD | 103 | 2.7% |
Geopolitical & Trade Policy Impact on Centaur Pharmaceuticals Private Limited's Gliclazide Exports
Centaur's export operations are currently navigating a complex geopolitical landscape. The ongoing Israel-Iran tensions have led to increased security risks in the Strait of Hormuz and the Red Sea–Suez Canal corridor, prompting major carriers to alter trade routes. This has resulted in extended transit times and elevated freight rates, impacting the cost-effectiveness and timeliness of pharmaceutical exports from India to Europe. (livemint.com) For Centaur, which relies heavily on these shipping lanes, such disruptions necessitate strategic adjustments in logistics and supply chain management.
In the United States, the push for pharmaceutical manufacturing reshoring and the imposition of tariffs on imported drugs have introduced additional challenges for Indian exporters. Centaur's acquisition of Bayshore Pharmaceuticals LLC can be seen as a strategic response to these developments, enabling the company to establish a local presence and potentially circumvent some of the trade barriers. (prysm.fi) This move reflects a proactive approach to maintaining competitiveness in a rapidly evolving market.
Furthermore, compliance with the European Union's falsified medicines directive requires stringent adherence to quality and safety standards. For Centaur, ensuring compliance with these regulations is crucial to sustaining and expanding its market share in the EU. The company's commitment to quality is evident in its successful USFDA audits and adherence to Good Manufacturing Practices (GMP). (moneycontrol.com)
Centaur Pharmaceuticals Private Limited — Regulatory Compliance & Quality Standards
Maintaining compliance with international regulatory standards is paramount for Centaur's export operations. The company has demonstrated a strong commitment to quality, as evidenced by its Pune finished dosage facility completing a USFDA audit with zero Form 483 observations, resulting in a No Action Indicated (NAI) compliance status. (moneycontrol.com) This achievement underscores Centaur's adherence to current Good Manufacturing Practices (cGMP) and its dedication to producing high-quality pharmaceutical products.
However, the evolving regulatory landscape, including the EU's falsified medicines directive and the US's emphasis on domestic manufacturing, necessitates continuous vigilance and adaptation. Centaur's proactive measures, such as acquiring U.S.-based entities and ensuring compliance with international standards, position the company to navigate these challenges effectively.
About Centaur Pharmaceuticals Private Limited
Centaur Pharmaceuticals Private Limited exports 6 products worth $11.1M. Beyond Gliclazide, top products include Metformin, Clonazepam, Alprazolam, Lorazepam, Tetracycline. View the complete Centaur Pharmaceuticals Private Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Gliclazide — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Gliclazide shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Centaur Pharmaceuticals Private Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 44 individual customs records matching Centaur Pharmaceuticals Private Limited exporting Gliclazide, covering 32 formulations to 10 countries via 15 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 109+ countries, 643+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Gliclazide Export Data from Centaur Pharmaceuticals Private Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Centaur Pharmaceuticals Private Limited's Gliclazide exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Centaur Pharmaceuticals Private Limited
Full Company Profile →
6 products · $11.1M total trade · 4 categories
Gliclazide Stats
Company Overview
Top Products by Centaur Pharmaceuticals Private Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Centaur Pharmaceuticals Private Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Gliclazide. For current shipment-level data, contact TransData Nexus.